| Carcinoma, Bronchogenic |
NCT02480634: Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 4 | 280 | NA | Zoledronic acid, Zometa, Radiotherapy | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Non-small Cell Lung Cancer, Bone Metastasis | 09/21 | 12/22 | | |
NCT02875457: Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin |
|
|
| Not yet recruiting | 3 | 100 | RoW | apatinib;etoposide and cisplatin, placebo;etoposide and cisplatin | Third Military Medical University | Small Cell Lung Cancer | 09/18 | 09/23 | | |
NCT02001168: Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB |
|
|
| Active, not recruiting | 3 | 392 | RoW | Pemetrexed, Alimta, Docetaxel, Taxotere, rh-Endostatin, Endostar, Cis-platinum, Platinol | Xinjiang Medical University | Non-small Cell Lung Cancer | 12/20 | 10/22 | | |
NCT02714010: EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC |
|
|
| Recruiting | 3 | 601 | RoW | EGFR-TKI, Gefitinib/Tarceva/Icotinib, whole brain radiotherapy, WBRT | Sun Yat-sen University | Non-Small Cell Lung Cancer | 12/21 | 12/22 | | |
NCT02938546: 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study |
|
|
| Not yet recruiting | 3 | 200 | RoW | 18F-FDG | Shanghai Chest Hospital | Non-small-cell Lung Cancer | 01/23 | 01/23 | | |
NCT02824458: A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations |
|
|
| Recruiting | 3 | 246 | RoW | Apatinib, YN968D1, Gefitinib, Iressa, Placebo | Sun Yat-sen University | EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors | 12/23 | 12/23 | | |
EMERGING, NCT01407822: Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2/3 | 72 | RoW | Erlotinib, Tarceva, Gemcitabine/cisplatin, Gemzar/cisplatin | Guangdong Association of Clinical Trials, Guangdong Provincial People's Hospital, Tianjin Medical University Cancer Institute and Hospital, Jilin Provincial Tumor Hospital, Jiangsu Cancer Institute & Hospital, Zhejiang Cancer Hospital, Peking University Cancer Hospital & Institute, Sun Yat-sen University, West China Hospital, The First Affiliated Hospital of Dalian Medical University, Peking University People's Hospital, Health Science Center of Xi'an Jiaotong University, Shanghai Zhongshan Hospital, Guangzhou General Hospital of Guangzhou Military Command, The First Affiliated Hospital of Guangzhou Medical University, Fujian Medical University Union Hospital, Linyi Tumour Hospital, Northern Jiangsu Province People's Hospital | Non-small Cell Lung Cancer | 04/18 | 12/22 | | |
NCT02726568: High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases |
|
|
| Recruiting | 2 | 30 | RoW | Icotinib, SRS | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer, Brain Metastases | 12/21 | 12/22 | | |
NCT02755675 / 2015-005642-59: uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung |
|
|
| Recruiting | 2 | 120 | Europe | 68Ga-NOTA-AE105 PET/CT | Rigshospitalet, Denmark | Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma, Large Cell Neuroendocrine Carcinoma of the Lung | 04/23 | 10/23 | | |
NCT02820116: The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 2 | 67 | RoW | Icotinib, Conmana | Beijing Haidian Hospital, Peking University People's Hospital, 307 Hospital of PLA, 309th Hospital of Chinese People's Liberation Army | Non-small Cell Lung Cancer(NSCLC) | 04/23 | 04/23 | | |
NCT01588028: A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1/2 | 36 | US | CH5424802 | Hoffmann-La Roche | ALK-Rearranged Non-Small Cell Lung Cancer | 09/15 | 09/15 | | |
|
|
|
NCT02619448: Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC |
|
|
| Recruiting | 1 | 12 | US | Carboplatin, Paraplatin, Paclitaxel, taxol, 70 Gy in 20 fractions over 4 weeks | State University of New York - Upstate Medical University | Non-small Cell Lung Cancer | 07/24 | 12/25 | | |
NCT01279798: Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L) |
|
|
| No Longer Available | N/A | | US | Lucanix® (belagenpumatucel-L), Lucanix | NovaRx Corporation | Non-small Cell Lung Cancer | | | | |
NCT02271139: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy |
|
|
| No Longer Available | N/A | | US | Alectinib | Genentech, Inc. | Non-Small Cell Lung Cancer | | | | |
NCT02824094: Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC |
|
|
| No Longer Available | N/A | | Japan | crizotinib | Pfizer | Neoplasms, Carcinoma, Non-Small-Cell Lung | | | | |
NCT02784158: An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer |
|
|
| No Longer Available | N/A | | US | Brigatinib, AP26113 | Ariad Pharmaceuticals | Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma | | | | |
NCT02547675: Rociletinib (CO-1686) USA Expanded Access Program |
|
|
| No Longer Available | N/A | | US | Rociletinib, CO-1686 | Clovis Oncology, Inc. | Non-small Cell Lung Cancer | | | | |
NCT01317953: Oral Green Tea Extract for Small Cell Lung Cancer |
|
|
| Available | N/A | | RoW | epigallocatechin gallate, EGCG | Shandong Cancer Hospital and Institute | Small Cell Lung Carcinoma | | | | |
NCT03077854: Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial |
|
|
| Recruiting | N/A | 64 | RoW | Functional Lung Avoidance Thoracic Radiotherapy, Standard Thoracic Radiotherapy | National Taiwan University Hospital | Small Cell Lung Cancer, Limited Stage, Stage III Non-small Cell Lung Cancer | 05/21 | 05/23 | | |
NCT03108560: Sublobar Resection Versus Lobectomy for cT1N0M0 Non-small-cell Lung Cancer |
|
|
| Recruiting | N/A | 600 | RoW | sublobar resection, lobectomy | Shanghai Zhongshan Hospital, Ruijin Hospital, RenJi Hospital, Fujian Medical University Union Hospital, The Second Affiliated Hospital of Dalian Medical University, First Affiliated Hospital of Wenzhou Medical University, Ningbo No.2 Hospital | Carcinoma, Non-Small-Cell Lung | 12/23 | 12/23 | | |
| Recruiting | N/A | 250 | Europe | Serum and plasma samples | Hospices Civils de Lyon | Non-small Cell Lung Cancer | 12/25 | 12/25 | | |
NCT01595074: Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy |
|
|
| Not yet recruiting | N/A | 950 | Canada | medical chart review, chart review, laboratory biomarker analysis | National Cancer Institute (NCI) | Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer | 01/00 | | | |